-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Bleeding Complications in Immune Thrombocytopenia

Program: Education Program
Session: Management of Challenging Bleeding Complications
Saturday, December 5, 2015, 7:30 AM-9:00 AM
Chapin Theater (W320), Level 3 (Orange County Convention Center)
Saturday, December 5, 2015, 4:00 PM-5:30 PM
W308, Level 3 (Orange County Convention Center)

Donald M. Arnold, MD, MSc

Medicine, McMaster University, Michael G. DeGroote School of Medicine, Hamilton, ON, Canada; Canadian Blood Services, Hamilton, ON, Canada

Disclosures: Arnold: Amgen: Consultancy , Research Funding ; GlaxoSmithKline: Research Funding ; Bristol Myers Squibb: Consultancy . Off Label Use: Rituximab is not licensed for the treatment of ITP..

See more of: Management of Challenging Bleeding Complications
See more of: Education Program
<< Previous Presentation | Next Presentation >>